Axial spondyloarthritis treatment patterns, clinical characteristics and patient-reported outcome collection in US rheumatology practices
Patients recently diagnosed with axSpA often initiated a biologic-containing treatment regimen as first-line therapy, contributing to improved symptom management compared with those without biologic treatment. More than half of patients did not receive guideline-recommended PRO assessments, highlighting the opportunity for increased symptom monitoring to guide clinical decision-making.
Authors
- Andrew L. Concoff (ORCID: https://orcid.org/0000-0001-8325-760X)
- Ariane Faucher
- L. Grinnell-Merrick
- Riley Taiji
- Francis Vekeman (ORCID: https://orcid.org/0000-0001-7957-3431)
- Courtney McDermott (ORCID: https://orcid.org/0000-0001-6294-868X)
- Raluca Ionescu-Ittu
- Rachelle Haber
- Tim Nguyen
- Jonathan Rodrigues
Institutions
- Novartis (Ireland) (IE)
- Statistical Research (United States) (US)
- Tris Pharma (United States) (US)
- Network Technologies (United States) (US)
Publication Details
- Journal
- Rheumatology Advances in Practice
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1093/rap/rkaf119
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00